New vaginal tablet shows promise in taming recurrent bacterial vaginosis

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to give written informed consent for participation in the clinical investigation, and to comply with all clinical investigation requirements. 2. Adult, post-menarchal, pre-menopausal women aged 18 years or older. 3. Diagnosis of BV according to Amsel's criteria, defined as having at least 3 of the 4 following criteria: * Thin, white, yellow, homogeneous discharge. * Clue cells on microscopy (\>20% of epithelial cells). * pH of vaginal fluid \>4.5. * Release of "fishy odour", i.e., a positive "whiff test" when alkali (10% KOH solution) is added. This symptom must be present. 4. Negative urine pregnancy test at screening. 5. Willing to refrain from using any intravaginal products (e.g., contraceptive creams, gels, foams, sponges, sex toys, lubricants or tampons, etc.) until Day 14. 6. Willing to use condoms during any sexual intercourse with a male sexual partner until the pHyph treatment is complete (Day 14). 7. Willing to use a method of contraception, e.g., condoms, hormonal contraception (oral, injectable, implantable, intravaginal, or transdermal), IUD (if a copper IUD is used, it must be combined with a condom) or intrauterine hormone-releasing system (IUS), during any sexual intercourse that might result in pregnancy from Visit 1 (Day 0) until Visit 4 (Day 25) to prevent pregnancy. Exclusion Criteria: 1. Patients with known or apparent signs of other infectious causes of vaginitis (e.g., vulvovaginal candidiasis, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex, or human papillomavirus) at screening. 2. History of or presence at screening (Day 0) of any other clinically significant disease or disorder, medical/surgical procedure, or trauma, which, in the opinion of the Investigator, may either put the patient at risk because of participation in the clinical investigation, or influence the results or the patient's ability to participate in the clinical investigation. 3. Anticipated menstruation during the first treatment period (Day 0 until Day 7). 4. Patients who are pregnant or breastfeeding. 5. Patients who are planning to conceive within the 25 days of the investigation. 6. Patients who were treated for BV within the 14 days preceding screening. 7. Patients who are currently receiving antibiotic therapy unrelated to BV or have received antibiotic therapy within the 14 days preceding screening. 8. Patients who have used any pH-modifying vaginal products within the 14 days preceding screening. 9. Patients who have received an investigational drug in a clinical trial within 30 days prior to screening. 10. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, to any of the product components. 11. The Investigator considers the patient unlikely to comply with clinical investigation procedures, restrictions and requirements.